| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01128842 | Advanced Malignant Solid Tumors | Drug: Neratinib + Capecitabine | Puma Biotechnology, Inc. | Phase 1 | 2010-04-01 | 2012-05-10 |
| NCT00838539 | Neoplasms|Malignant Carcinoma | Drug: Neratinib|Drug: Temsirolimus | Puma Biotechnology, Inc. | Phase 1 | 2009-04-01 | 2016-11-22 |
| NCT02932280 | Solid Tumor|Central Nervous System Tumor|Lymphoma|Leukemia | Drug: Neratinib | Memorial Sloan Kettering Cancer Center|Milton S. Hershey Medical Center|M.D. Anderson Cancer Center|Stanford University|Arkansas Children's Hospital Research Institute|Alberta Children's Hospital|Phoenix Children's Hospital|University of Texas | Phase 1|Phase 2 | 2016-10-01 | 2017-02-15 |
| NCT01142063 | Healthy | Drug: Neratinib|Drug: Neratinib|Drug: Neratinib|Drug: Neratinib | Puma Biotechnology, Inc. | Phase 1 | 2010-06-01 | 2012-05-10 |
| NCT00958724 | Advanced Malignant Solid Tumors | Drug: treatment with neratinib (HKI-272) + vinorelbine | Puma Biotechnology, Inc. | Phase 1 | 2009-07-01 | 2012-05-10 |
| NCT01111825 | Breast Cancer | Drug: Temsirolimus|Drug: Neratinib | Puma Biotechnology, Inc. | Phase 1|Phase 2 | 2010-04-01 | 2016-10-05 |
| NCT03065387 | Malignant Neoplasm of Breast|Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites|Malignant Neoplasms of Independent (Primary) Multiple Sites|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Mesothelial and Soft Tissue|Malignant Neoplasms of Respiratory and Intrathoracic Organs|Malignant Neoplasms of Thyroid and Other Endocrine Glands|Malignant Neoplasms of Urinary Tract|Neoplasms of Uncertain or Unknown Behavior | Drug: Neratinib|Drug: Everolimus|Drug: Palbociclib|Drug: Trametinib | M.D. Anderson Cancer Center|Pfizer|Puma Biotechnology, Inc. | Phase 1 | 2017-04-01 | 2017-02-28 |
| NCT01960023 | Colorectal Cancer | Drug: Cetuximab|Drug: Neratinib | NSABP Foundation Inc | Phase 1|Phase 2 | 2013-10-01 | 2016-05-05 |
| NCT01827267 | HER2-mutant Non-Small Cell Lung Cancer | Drug: neratinib|Drug: temsirolimus | Puma Biotechnology, Inc. | Phase 2 | 2013-05-01 | 2017-03-02 |
| NCT02236000 | Breast Cancer | Drug: Neratinib|Drug: T-DM1 | NSABP Foundation Inc|Puma Biotechnology, Inc. | Phase 1|Phase 2 | 2014-08-01 | 2017-02-20 |
| NCT00781430 | Hepatic Insufficiency | Drug: Neratinib (HKI-272) | Puma Biotechnology, Inc. | Phase 1 | 2009-04-01 | 2012-05-10 |
| NCT01956253 | Bladder Cancer | Drug: Neratinib | UNC Lineberger Comprehensive Cancer Center | | 2013-07-01 | 2017-03-10 |
| NCT01423123 | Breast Cancer | Drug: Paclitaxel|Biological: trastuzumab|Drug: Neratinib | NSABP Foundation Inc|Pfizer | Phase 1 | 2011-05-01 | 2014-07-07 |
| NCT00741260 | Breast Cancer | Drug: Neratinib|Drug: capecitabine | Puma Biotechnology, Inc. | Phase 1|Phase 2 | 2008-12-01 | 2016-06-22 |
| NCT02334501 | Healthy | Drug: Lansoprazole|Drug: Neratinib | Puma Biotechnology, Inc. | Phase 1 | 2014-08-01 | 2016-05-09 |
| NCT01953926 | Solid Tumors | Drug: Neratinib|Drug: Paclitaxel|Drug: Fulvestrant | Puma Biotechnology, Inc. | Phase 2 | 2013-09-30 | 2017-02-17 |
| NCT00864487 | Healthy Subjects | Drug: Neratinib | Puma Biotechnology, Inc. | Phase 1 | 2009-04-01 | 2012-05-10 |
| NCT00932464 | Healthy | Drug: Neratinib|Drug: Neratinib | Puma Biotechnology, Inc. | Phase 1 | 2012-08-01 | 2012-05-10 |
| NCT02673398 | HER2 Positive Breast Carcinoma|Recurrent Breast Carcinoma|Stage IV Breast Cancer | Other: Comprehensive Geriatric Assessment|Other: Laboratory Biomarker Analysis|Drug: Neratinib|Other: Pharmacological Study | City of Hope Medical Center|National Cancer Institute (NCI)|Puma Biotechnology, Inc. | Phase 2 | 2016-10-01 | 2016-11-30 |
| NCT01670877 | Breast Neoplasms | Drug: Neratinib|Drug: Fulvestrant|Drug: Trastuzumab | Washington University School of Medicine | Phase 2 | 2012-12-11 | 2017-02-08 |
